<DOC>
	<DOCNO>NCT02573259</DOCNO>
	<brief_summary>Protocol B8011001 Phase 1 , open-label , multi center , multiple-dose , dose escalation , safety , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) study PF-06801591 administer intravenously/subcutaneous previously treat adult patient locally advance metastatic melanoma , SCCHN , ovarian carcinoma , sarcoma , relapse refractory cHL solid tumor . This 2 Part study ass safety tolerability increase dose level intravenous ( IV ) /subcutaneous ( SC ) PF-06801591 Part 2 establish recommend Phase 2 dose ( RP2D ) .</brief_summary>
	<brief_title>A Dose Escalation Study Of PF-06801591 In Melanoma , Head And Neck Cancer ( SCCHN ) , Ovarian , Sarcoma , Hodgkin Lymphoma Other Solid Tumors</brief_title>
	<detailed_description>Protocol B8011001 Phase 1 , open-label , multi center , multiple-dose , dose escalation , safety , PK , PD study PF-06801591 administer intravenously/subcutaneous previously treat adult patient locally advance metastatic melanoma , SCCHN , ovarian carcinoma , sarcoma , relapse refractory cHL solid tumor . The first part study , Part 1 dose escalation , assess safety tolerability increase dose level intravenous/subcutaneous PF-06801591 patient select advanced metastatic solid tumor order establish maximum tolerate dose ( MTD ) use modify Toxicity Probability Interval ( mTPI ) design . The second part study , Part 2 dose expansion , expand enrollment restrict number tumor type dos base finding Part 1 establish recommend Phase 2 dose ( RP2D ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>Performance status 0 1 Histological cytological diagnosis locally advance metastatic melanoma , SCCHN , ovarian cancer , sarcoma , relapse refractory cHL , solid tumor responsive anti PD1/PDL1 therapy . Patient receive least 1 therapy recurrent metastatic disease , include standard care investigational therapy . At least one measurable lesion define RECIST version 1.1 , ( cHL ) least 1 fluordeoxyglucose positron emission tomography ( FDG PET ) avid ( Deauville 4/5 ) measurable lesion &gt; 1.5 cm define Response Criteria Malignant Lymphoma previously irradiate . Adequate Renal , Liver , bone marrow function For Part 1B expansion cohort : patient consent undergo pre treatment treatment biopsy . Exclusion Criteria Active brain leptomeningeal metastasis . Ocular melanoma Active , know suspected autoimmune disease . Patients vitiligo , type I diabetes mellitus , residual hypothyroidism due autoimmune condition require hormone replacement , psoriasis require systemic immunosuppressive treatment ( e.g . prednisone &gt; 10 mg equivalent daily ) , condition expect recur absence external trigger permit enroll . Diagnosis prior immunodeficiency organ transplant require immunosuppressive therapy , prior allogenic bone marrow hematopoietic stem cell transplant . History Grade â‰¥3 immune mediate AE ( include AST/ALT elevation consider drug relate cytokine release syndrome ) consider related prior immune modulatory therapy ( eg , immune checkpoint inhibitor , co stimulatory agent , etc . ) require immunosuppressive therapy . Active hepatitis B C , HIV . Other potentially metastatic malignancy within past 5 year . For Part 2 : prior treatment PD1 PDL1 antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>open label</keyword>
	<keyword>dose response</keyword>
	<keyword>multiple ascend dose</keyword>
	<keyword>immunogenicity</keyword>
</DOC>